CO2018001407A2 - Composiciones con potenciadores de permeación para suministro de fármacos - Google Patents

Composiciones con potenciadores de permeación para suministro de fármacos

Info

Publication number
CO2018001407A2
CO2018001407A2 CONC2018/0001407A CO2018001407A CO2018001407A2 CO 2018001407 A2 CO2018001407 A2 CO 2018001407A2 CO 2018001407 A CO2018001407 A CO 2018001407A CO 2018001407 A2 CO2018001407 A2 CO 2018001407A2
Authority
CO
Colombia
Prior art keywords
compositions
agent
administration
matrix forming
drug delivery
Prior art date
Application number
CONC2018/0001407A
Other languages
English (en)
Spanish (es)
Inventor
Daniel S Kohane
Rong Yang
Lily Yun Lin
Original Assignee
Childrens Medical Center
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Massachusetts Inst Technology filed Critical Childrens Medical Center
Publication of CO2018001407A2 publication Critical patent/CO2018001407A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/335—Polymers modified by chemical after-treatment with organic compounds containing phosphorus
    • C08G65/3353—Polymers modified by chemical after-treatment with organic compounds containing phosphorus containing oxygen in addition to phosphorus
    • C08G65/3355—Polymers modified by chemical after-treatment with organic compounds containing phosphorus containing oxygen in addition to phosphorus having phosphorus bound to carbon and oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G79/00—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
    • C08G79/02—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing phosphorus
    • C08G79/04—Phosphorus linked to oxygen or to oxygen and carbon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CONC2018/0001407A 2015-08-05 2018-02-13 Composiciones con potenciadores de permeación para suministro de fármacos CO2018001407A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562201199P 2015-08-05 2015-08-05
PCT/US2016/045908 WO2017024282A1 (en) 2015-08-05 2016-08-05 Compositions with permeation enhancers for drug delivery

Publications (1)

Publication Number Publication Date
CO2018001407A2 true CO2018001407A2 (es) 2018-07-19

Family

ID=57943671

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0001407A CO2018001407A2 (es) 2015-08-05 2018-02-13 Composiciones con potenciadores de permeación para suministro de fármacos

Country Status (21)

Country Link
US (2) US11110175B2 (https=)
EP (1) EP3331547A4 (https=)
JP (2) JP7046793B2 (https=)
KR (1) KR102826997B1 (https=)
CN (1) CN108135967B (https=)
AU (1) AU2016304585B2 (https=)
BR (1) BR112018002227A2 (https=)
CA (1) CA2994702A1 (https=)
CL (1) CL2018000299A1 (https=)
CO (1) CO2018001407A2 (https=)
CR (1) CR20180128A (https=)
EA (1) EA201890458A1 (https=)
EC (1) ECSP18017254A (https=)
HK (1) HK1252531A1 (https=)
IL (1) IL257329A (https=)
MA (1) MA43574A (https=)
MX (1) MX2018001571A (https=)
PE (1) PE20181153A1 (https=)
PH (1) PH12018500262A1 (https=)
WO (1) WO2017024282A1 (https=)
ZA (1) ZA201800960B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180128A (es) 2015-08-05 2018-04-24 Childrens Medical Center Composiciones con potenciadores de permeación para suministro de fármacos
JP2019512447A (ja) * 2016-03-31 2019-05-16 ダウ グローバル テクノロジーズ エルエルシー 疎水性シリカ粒子の作製方法
CN109937033A (zh) * 2016-09-14 2019-06-25 儿童医学中心公司 用于药物递送的具有渗透增强剂的组合物
US11173210B2 (en) * 2017-10-24 2021-11-16 Sonoran Biosciences, Inc. Temperature-responsive degradable hydrogels
CN112020359A (zh) 2018-02-09 2020-12-01 分贝治疗公司 含有抗铂化学保护剂的高渗药物组合物
WO2019193513A1 (en) * 2018-04-03 2019-10-10 Hyderabad Eye Research Foundation Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics
AU2019321429B2 (en) 2018-08-15 2022-12-08 Aiviva Biopharma, Inc. Multi-kinase inhibitors of VEGF and TGF beta and uses thereof
CA3110566A1 (en) * 2018-08-31 2020-03-05 Children's Medical Center Corporation Compositions with synergistic permeation enhancers for drug delivery
AU2019386968B2 (en) * 2018-11-26 2022-12-22 Aiviva Biopharma, Inc. Pharmaceutical biodissolvable gels for drug delivery
CN109513036B (zh) * 2019-01-11 2021-04-20 四川大学 一种受体温诱导可自动关闭抗菌功能的胶原蛋白材料
CN111840553A (zh) * 2019-04-15 2020-10-30 湖州依诺唯新药物制剂有限公司 脂性药物制剂及其应用
CN110028624A (zh) * 2019-04-16 2019-07-19 昆明理工大学 基于半纤维素复合温敏凝胶的制备方法及应用
CN114040782A (zh) 2019-04-30 2022-02-11 威斯康星州医药大学股份有限公司 跨鼓膜递送平台及其用途
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
WO2022013642A1 (en) * 2020-07-16 2022-01-20 3M Innovative Properties Company Phosphate-containing copolymers for virulence suppression
CA3188400A1 (en) * 2020-08-03 2022-02-10 Daniel S. Kohane Thermo-sensitive permeation enhancing formulations for drug delivery
CN111849597B (zh) * 2020-08-04 2022-08-09 中山华明泰科技股份有限公司 一种烷烃煤基油合成润滑剂的制备方法和应用
US12508221B2 (en) * 2020-09-11 2025-12-30 PS Therapy Ltd Topical compositions and methods of use
CN113304104A (zh) * 2021-05-11 2021-08-27 四川大学 一种智能温敏型缓释凝胶及其制备方法
WO2022256291A1 (en) * 2021-06-01 2022-12-08 President And Fellows Of Harvard College Hydrogel devices for drug delivery to the ear
EP4279061A1 (en) * 2022-05-18 2023-11-22 Acousia Therapeutics GmbH Aqueous gel composition
WO2024015764A1 (en) * 2022-07-11 2024-01-18 PriZm, LLC 3,5-diiodothyropropionic acid compositions and methods of use thereof
WO2024233921A1 (en) * 2023-05-10 2024-11-14 Cornell University Compositions for the transtympanic delivery of antibiotics and methods for using the same
AU2024331964A1 (en) * 2023-08-31 2026-03-12 Fluidx Medical Technology, Inc. Polyelectrolyte hydrogel formulations and methods for making and using the same
CN118078964B (zh) * 2024-04-24 2024-07-12 长春生物制品研究所有限责任公司 重组人干扰素软膏及其制备方法
GB202405996D0 (en) 2024-04-29 2024-06-12 Arecor Ltd Novel compositions
GB202405997D0 (en) 2024-04-29 2024-06-12 Arecor Ltd Novel compositions
CN119385873B (zh) * 2024-10-28 2025-09-05 浙江章光101有限公司 一种防脱精华露及其制备方法
CN119745882B (zh) * 2024-12-26 2025-09-23 中国医学科学院放射医学研究所 一种基因递送纳米粒子及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798290A (en) 1971-07-26 1974-03-19 Stauffer Chemical Co Mixed polyalkylene glycol polyphosphorus compound
FR2393586A1 (fr) 1977-06-08 1979-01-05 Roussel Uclaf Dispositif pour l'administration de substances medicamenteuses
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
EP0725628B1 (en) 1994-08-30 2001-11-07 Alcon Laboratories, Inc. Thermally-gelling drug delivery vehicles containing cellulose ethers
JPH11510837A (ja) * 1995-07-28 1999-09-21 フォーカル，インコーポレイテッド 薬物送達のための制御された放出薬剤および組織処置薬剤としての使用のためのマルチブロック生分解性ヒドロゲル
US5684051A (en) 1996-04-24 1997-11-04 Hercules Incorporated Medical devices with improved elastic response
WO1998017315A2 (en) * 1996-10-24 1998-04-30 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
WO2000007603A2 (en) 1998-08-04 2000-02-17 Madash Llp End modified thermal responsive hydrogels
US8197461B1 (en) * 1998-12-04 2012-06-12 Durect Corporation Controlled release system for delivering therapeutic agents into the inner ear
MXPA03004546A (es) 2000-11-22 2003-09-10 Rxkinetix Inc Tratamiento de mucositis.
ATE354338T1 (de) 2001-03-27 2007-03-15 Lilly Co Eli Kit mit einer spritzennadel mit seitenöffnung zur bereitung eines medikaments in einer injektionsstiftkartusche
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US20070269379A1 (en) 2003-07-23 2007-11-22 Samir Mitragotri Penetration Enhancer Combinations for Transdermal Delivery
RU2319508C2 (ru) 2003-07-31 2008-03-20 ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи Диспергируемый препарат противовоспалительного агента
EP1697382A4 (en) 2003-12-10 2008-11-05 Activbiotics Inc ANALOGUES OF RIFAMYCIN AND USES THEREOF
US9056061B2 (en) * 2005-09-23 2015-06-16 Alza Corporation Transdermal nicotine salt delivery system
AU2006326456A1 (en) 2005-12-14 2007-06-21 Activbiotics Pharma Llc Rifamycin analogs and uses thereof
WO2007120818A2 (en) 2006-04-12 2007-10-25 Massachusetts Institute Of Technology Compositions and methods for inhibiting adhesions
US8822410B2 (en) * 2008-05-19 2014-09-02 Children's Medical Center Corporation Tympanic membrane permeating ear drops and uses thereof
US8658699B2 (en) 2008-05-19 2014-02-25 Massachusetts Institute Of Technology Chemical permeation enhancers enhance nerve blockade by toxins
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
JP6013736B2 (ja) 2008-12-22 2016-10-25 オトノミ—，インク． 耳の障害の処置のための耳感覚細胞モジュレータ組成物の制御放出及びその方法
WO2011049958A2 (en) 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
KR20150027684A (ko) 2013-08-29 2015-03-12 삼성에스디아이 주식회사 편광판, 이의 제조방법 및 이를 포함하는 액정표시장치
CR20180128A (es) 2015-08-05 2018-04-24 Childrens Medical Center Composiciones con potenciadores de permeación para suministro de fármacos
CN109937033A (zh) 2016-09-14 2019-06-25 儿童医学中心公司 用于药物递送的具有渗透增强剂的组合物
WO2019210107A1 (en) 2018-04-25 2019-10-31 Otonomy, Inc. Otic formulations for drug-induced ototoxicity
CA3110566A1 (en) 2018-08-31 2020-03-05 Children's Medical Center Corporation Compositions with synergistic permeation enhancers for drug delivery
CA3188400A1 (en) 2020-08-03 2022-02-10 Daniel S. Kohane Thermo-sensitive permeation enhancing formulations for drug delivery

Also Published As

Publication number Publication date
WO2017024282A1 (en) 2017-02-09
PE20181153A1 (es) 2018-07-17
JP7046793B2 (ja) 2022-04-04
BR112018002227A2 (pt) 2018-09-18
IL257329A (en) 2018-03-29
JP2018522905A (ja) 2018-08-16
EP3331547A1 (en) 2018-06-13
EA201890458A1 (ru) 2019-01-31
PH12018500262A1 (en) 2018-08-13
KR102826997B1 (ko) 2025-07-01
US11110175B2 (en) 2021-09-07
CN108135967B (zh) 2022-06-28
US12053527B2 (en) 2024-08-06
CR20180128A (es) 2018-04-24
CL2018000299A1 (es) 2018-07-06
AU2016304585B2 (en) 2023-04-06
CA2994702A1 (en) 2017-02-09
KR20180030416A (ko) 2018-03-22
US20180228903A1 (en) 2018-08-16
ZA201800960B (en) 2018-12-19
AU2016304585A1 (en) 2018-03-01
MX2018001571A (es) 2018-09-06
HK1252531A1 (zh) 2019-05-31
JP2021178838A (ja) 2021-11-18
US20220040309A1 (en) 2022-02-10
EP3331547A4 (en) 2019-08-21
MA43574A (fr) 2018-11-14
ECSP18017254A (es) 2018-10-31
CN108135967A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
CO2018001407A2 (es) Composiciones con potenciadores de permeación para suministro de fármacos
Weers Inhaled antimicrobial therapy–barriers to effective treatment
DOP2019000117A (es) Nuevos derivados de quinolina
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
CL2017003152A1 (es) Composiciones de hidroxipropil beta-ciclodextrina y métodos
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2016013301A (es) Composiciones farmaceuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quistica.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
UY37271A (es) Composiciones nasales de cannabinoides
UY37831A (es) Nuevos derivados de quinolina
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
MY187047A (en) Selective pyy compounds and uses thereof
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
BR112017003219A2 (pt) formulação de acetato de abiraterona e métodos de uso
MX2021007453A (es) Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo.
CL2021001244A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos de los mismos
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
BR112017004552A2 (pt) composições farmacêuticas
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
WO2019204363A3 (en) Selective delivery of therapeutic and imaging agents
CL2016003271A1 (es) Métodos para tratar infecciones
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
MX389811B (es) Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea